|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the Department of Cell and Neurobiology, Institute
of Anatomy, and Department of Hematology and Oncology, University
Hospital Charité, Humboldt University, Berlin, Germany; and
Department of Biochemistry and Tumor Biology, Clinic of Obstetrics and
Gynecology, Medical School, Hannover, Germany.
Treatment of different human leukemia cell variants with the
anthracycline adriamycin was associated with a rapid activation of the
proteasome. Thus, proliferating U937, TUR, and retrodifferentiated U937
cells exhibited a 4.3-fold, 5.8-fold, and 4.3-fold proteasome activation within 15 minutes after adriamycin treatment, respectively. In contrast, little if any proteasome activation was detectable in a
growth-arrested differentiated U937 population following adriamycin
treatment. Further analysis of this mechanism revealed a significant
reduction of adriamycin-induced proteasome activity after inhibition of
poly(ADP-ribose) polymerase (PARP) by 3-aminobenzamide (3-ABA) in the
proliferating leukemic cell types. These findings suggested that PARP
is involved in the regulation of drug-induced proteasome activation.
Indeed, anti-PARP immunoprecipitation experiments of adriamycin-treated
cells revealed increasing levels of coprecipitated, enzymatically
active proteasome particularly in the proliferating cell variants in
contrast to the differentiated U937 cells, with a maximum after 15 minutes, and sensitivity to PARP inhibition by 3-ABA. The
specific role of the PARP was investigated in U937 and TUR cell clones
stably transfected with a constitutively active antisense PARP (asPARP)
vector. Thus, asPARP-TUR cells developed a 25-fold increased
sensitivity to adriamycin treatment. Furthermore, we investigated
leukemic blasts isolated from acute myelogenous leukemia patients
and obtained a similarly enhanced proteasome activity after adriamycin
treatment, which was dependent on the PARP and thus could be
coprecipitated with anti-PARP antibodies. Transient transfection of
leukemic blasts with the asPARP vector significantly reduced the
adriamycin-induced proteasome activation. These data suggest that the
PARP-associated nuclear proteasome activation represents a potential
target within chemotherapeutic defense mechanisms developed by leukemia cells.
(Blood. 2001;97:2830-2838) Chemotherapeutic treatment of acute myelogenous
leukemia (AML) achieves complete remission in approximately 60% to
70% of adult AML. However, many patients obtaining a complete
remission will still suffer from leukemic recurrence.1-3
To improve the efficiency of antileukemic drugs, closer insights into
the cellular defense mechanisms of leukemic cells are required.
Common chemotherapies for treatment of AML are based on DNA
intercalating antitumor drugs such as the nucleoside analog
cytosine-arabinoside (AraC),4 etoposide
(VP-16),5 and compounds directly liberating free oxygen
radicals, such as anthracyclines.6 The cytotoxic action of
anthracyclines by the generation of free radicals has been demonstrated
both in vitro and in vivo.7-9 Radical production can be
associated with intratumor drug metabolism or redox cycling reactions,10,11 particularly in close proximity to the
chromatin.7,8,11 Oxidative stress in the nucleus
contributes to the formation of oxidatively damaged histones, which can
modify DNA by cross-linking12,13 and therefore can alter
chromatin dynamic processes such as DNA transcription, replication, and
repair. Thus, the selective and efficient degradation of oxidatively
damaged nuclear proteins appears to be a requirement for maintaining
genomic integrity. However, such an antioxidative defense system might
also be used by certain leukemia cells to cope with nuclear damages
induced by radical-producing compounds. Consequently, these resistant leukemia cells survive chemotherapy and potentially develop a tumor relapse.
Usually, oxidatively damaged proteins undergo selective proteolysis via
an adenosine triphosphate- and ubiquitin-independent pathway.14 The 20S proteasome, a large 700-kd
multicatalytic and multisubunit proteinase located in the cytosol and
in the nucleus,15 is largely responsible for the selective
degradation of such damaged proteins,16,17 including
oxidatively damaged DNA-bound histones.18 Previous studies
have demonstrated an elevated proteasome activity in leukemia
cells19 and a possible relationship to the proliferative
activity.20
Other work has described an activation of the proteasome in vitro by
interaction with poly(ADP-ribosyl)ated poly(ADP-ribose) polymerase (PARP).21 This enzyme was demonstrated to be
highly activated by both oxidative stress and chemotherapy
treatment.19,22 PARP is a nuclear enzyme that catalyzes
the synthesis and transfer of poly(ADP-ribose) from NAD+
molecules to various nuclear acceptor proteins as well as to itself
23 and may therefore play also a role in DNA transcription and repair.24 In this context, previous studies have
suggested that PARP inhibition modulates chemotherapy toxicity in the
same direction.6,25,26 Proposed mechanisms for antitumor
activity of PARP inhibition during chemotherapy involve disturbance of DNA repair,6,27 induction of specific resistance-related
molecules,28 or a loss of amplified
oncogenes.29 Interestingly, PARP is also discussed as a
useful target for enhancing the cytotoxicity of several
chemotherapeutic agents,4-6,30 particularly
adriamycin.31 However, little is known about the possible
mechanisms of adriamycin-induced chemotherapy potentiation by PARP and
its relationship to a proteasome activation in vivo.
The extent of nuclear damage and cytotoxicity after application of
antileukemic drugs depends on the type and possibly on the state of
development of the targeted tumor cells. Therefore, we used in this
study a well-established differentiation-retrodifferentiation system of
human U937 myelomonocytic leukemia cells,32-34 which allows the investigation of differentiation-dependent alterations in
closely related populations. Treatment of human U937 leukemia cells
with 12-O-tetradecanoylphorbol-13-acetate (TPA) is accompanied by
growth arrest and induction of a monocytic differentiation program.35 During this differentiation process, the cells
acquire a variety of morphologic and nonmalignant functional changes
associated with monocytes or macrophages.32 These
TPA-differentiated U937 cells remain and survive in a transient G0
growth-arrest cycle for approximately 2 to 3 weeks.33
Thereafter, the differentiated population loses all acquired
differentiation markers and re-enters the proliferative cell cycle by a
retrodifferentiation process, developing again the undifferentiated
U937 phenotype.33 Other work has characterized a U937
subclone, termed TUR, which is unable to differentiate along the
monocytic lineage and continues to proliferate in the presence of
TPA.36 Moreover, human TUR leukemia cells demonstrate
aggressively developing tumors in scid mice in contrast to the parental
U937 cells.37 These populations of U937 cell variants,
which resemble certain states of differentiation and proliferation,
were used in the present study to investigate the adriamycin-induced
activation of the nuclear protesome and a possible involvement of the
proteasome in developing adriamycin resistance.
Cell culture of human leukemic cell lines and isolated leukemic
patient blasts
Treatment with adriamycin, AraC, and VP-16
Isolation of nuclei and measurement of the nuclear proteasomal proteolytic activity Highly purified nuclei without detectable contamination of other cellular compartments were obtained from the human leukemic cell lines by the procedure of Emig et al.38 The isolated nuclei were lysed by 5 freeze-thawing cycles in 10 mM HEPES (pH 7.5), 24 mM KCl, 10 mM MgCl2, and 0.5 mM dithiothreitol. The proteasome activity in nuclear lysates was measured by the peptidase activity toward the hydrophobic fluorogenic peptide succinyl-leucine-leucine-valine-tyrosine-methylcoumaryl-amide (suc-LLVY-MCA) by incubation with 50 mM Tris-HCl (pH 7.8), 20 mM KCl, 5 mM MgOAc, 0.5 mM dithiothreitol, and 200 µM suc-LLVY-MCA for 1 hour at 37°C in the presence and absence of 10 µM lactacystin. After incubation for 2 hours at 37°C, the reaction was stopped by the addition of an equal volume of ice-cold ethanol and a 10-fold volume of 125 mM sodium borate (pH 9.0). Thereafter, fluorescence intensity was determined at 380 nm excitation and 440 nm emission wavelength.Immunoblot analysis Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed in a 15% (for detection of proteasome subunits) and in a 10% (for detection of PARP) separation gel. Electrophoresis was standardized using prestained low molecular weight markers (Bio-Rad, Munich, Germany). Proteasome subunits were detected with a polyclonal rabbit antiproteasome antibody (Affiniti Research Products), and PARP was detected with a polyclonal rabbit anti-PARP antibody (a kind gift from Dr Schweiger, Berlin, Germany). For control blots a monoclonal mouse anti-green fluorescent protein (GFP) antibody (Clontech, Palo Alto, CA) and a polyclonal rabbit antiactin antibody (Sigma) were used, respectively. After incubation with an appropriate peroxidase-conjugated secondary antibody, the blots were developed using an enhanced chemiluminescence (ECL) detection kit (Amersham, Uppsala, Sweden).Immunoprecipitation experiments Immunoprecipitation experiments were performed in lysates of nuclei isolated from adriamycin-treated human leukemic cell lines and adriamycin-treated human leukemic patient blasts. For this technique a rabbit anti-PARP antibody was used with a modified procedure by Zwilling et al.39 The primary antibody reaction was performed in 50 mM Tris (pH 7.8) containing 150 mM NaCl (Tris-buffed saline), 0.1% bovine serum albumin, 100 µg nuclear lysates, and 1µL rabbit anti-PARP immunoglobulin G (IgG) (5 µg/µL) for 1 hour at 4°C. For secondary antibody reactions, 1 µL donkey antirabbit IgG (5 µg/µL) was added and incubated for 1 hour at 4°C. Binding of the secondary antibody was detected by using an ECL kit. Immunoprecipitations were initiated by adding 20 µL protein A-Sepharose (equilibrated with an equal volume of 50 mM Tris, 150 mM NaCl, and 0.1% bovine serum albumin, pH 8.0) for a 1-hour incubation at 4°C. Control immunoprecipitations were performed with the secondary antibody alone and the protein A-Sepharose. The Sepharose beads were centrifuged (14 000g for 30 minutes) and washed 5 times with Tris-buffered saline. Sepharose-bound proteins were separated by 15% SDS-PAGE, transblotted to nitrocellulose membranes, and incubated either with a polyclonal goat anti-PARP IgG or a polyclonal rabbit anticore-proteasome IgG.Measurement of oxidatively modified nuclear proteins Oxidatively modified nuclear proteins were determined by derivatization of protein-bound carbonyl moieties with dinitrophenylhydrazine (DNPH) according to Reznick and Packer.40 For this assay, 1.5 mg nuclear protein was derivatized with DNPH, precipitated with trichloroacetic acid, extensively washed with ethanol/ethylacetate (1:1 vol/vol), and redissolved in guanidinhydrochloride solution. Dinitrophenylhydrazones were determined spectrophotometrically at 370 nm.Detection of covalent DNA-protein cross-links Endogenous proteins were labeled with [3H]lysine for 5 population doublings by addition of 37 kBq (1 µCi) [3H]lysine (Amersham) to 5 × 105 U937, antisense PARP (asPARP)-U937, TUR, or asPARP-TUR cells in culture medium, respectively. The cells were washed 3 times in culture medium to remove nonincorporated radioactivity and cultured further on in the presence of 10 7 M adriamycin with or without a 30-minute
preincubation of 1 mM 3-ABA for up to 24 hours. At the time points
indicated, the nuclei of the labeled and treated cells were isolated
and lysed as described above. Covalent DNA-protein cross-links were
separated by nonreducing SDS-urea electrophoresis in a 3% stacking
gel and a 2-phase separation gel system (5%/20%) as described
previously.41 Whereas noncovalently bound proteins as well
as other proteins were detectable in the lower 20% gel phase, the DNA
and proteins covalently associated with DNA could be detected by silver
stain and were quantified by scintillation counting of the ethidium
bromide-stained DNA bands.
Alkaline single-cell electrophoresis DNA damage was investigated by alkaline single-cell gel electrophoresis (comet assay), which has been proven as a sensitive method for the detection of low levels of DNA damages.42,43 Alkaline single-cell gel electrophoresis was performed as described by Singh et al.44 Briefly, the cells were centrifuged, resuspended in PBS/0.5% low melting point agarose at 37°C, and 75 µL of the mixture was added onto a frosted glass microscope slide precoated with 100 µL of 1% melting point agarose. The slides were incubated 4°C for 10 minutes to allow polymerization of the agarose. The slides were immersed in cell lysis buffer (2.5 M NaCl, 100 mM ethylenediaminetetraacetic acid, 10mM Tris, 300 mM NaOH, 10% DMSO, and 1% Triton X-100, pH 10) at 4°C for 1 hour in the dark and placed in a horizontal alkaline electrophoresis unit (300 mM NaOH,1 mM ethylenediaminetetraacetic acid, pH 13) for 60 minutes to allow DNA unwinding. Thereafter, electrophoresis was performed at 20 V (1 V/cm, 300 mA) for 30 minutes, and the slides were gently neutralized (0.4 M Tris-HCl, pH 7.5) for 3 × 15 minutes. The extent of DNA migration was visualized after ethidium bromide staining using an Olympus BX-50 fluorescence microscope.Cloning of an asPARP vector Total RNA was isolated from BV2 cells (RNeasy Maxi Kit, Qiagen, Valencia, CA) followed by a complementary DNA synthesis (cDNA Synthesis Kit, Clontech) with a random primer hexamer and an amplification of the DNA of interest by polymerase chain reaction (PCR) (MJ Research, Waltham, MA). The PCR amplification product (a 650-base pair asPARP-containing fragment) was ligated into the GFP-coding pTracer CMV2 vector (Invitrogen, Carlsbad, CA) and amplified in competent Escherichia coli cells (Genotype TOP10F'). The successful cloning of the asPARP fragment was confirmed by sequencing analysis.Stable transfection of human leukemic cell lines with the asPARP vector U937 and TUR cells (107/mL) were incubated with 20 µg of either the pTracer CMV2 vector alone or the asPARP-containing vector in 500 µL RPMI 1640 medium. The cells were electroporated with a 250 V/960 µF pulse and then cultured in complete culture medium for 48 hours to allow expression of the zeocin gene. Thereafter, stably transfected U937 and TUR cells were selected with culture medium containing 100 µg/mL zeocin for the next 4 weeks, in each case. Long-term culture of stably transfected cells was maintained in culture medium with 50 µg/mL zeocin.Transient transfection of human leukemic patient blasts with the asPARP vector Freshly isolated human blasts from AML patients were transiently transfected by a lipofectin method. Blasts were transfected in serum-free RMPI 1640 medium with 12 µg vector DNA and 60 µL Rotifect (Carl-Roth, Karlsruhe, Germany) in a total volume of 20 mL for 5 hours. After removal of the transfection solution, blasts were cultivated in RMPI 1640 medium supplemented with 10% FCS. The successful transfection was determined by detection of the GFP in a Western blot and in a fluorescence microscope.
Proliferating U937 human leukemia cells were treated with
sublethal concentrations of AML therapy compounds, including DNA intercalating and oxygen radical-generating drugs, to investigate metabolization effects and repair mechanisms of damaged proteins by the
nuclear proteasome. The proteasome activity in the nuclei was measured
as lactacystin-sensitive cleavage of the proteasome substrate
suc-LLVY-MCA (Figure 1). Following
adriamycin treatment of U937 cells, the proteasome activity increased
about 4.3-fold after 15 minutes and subsequently returned to control
level after 60 minutes (Figure 1). In contrast, treatment with DNA
structure-modifying agents such as VP-16 and AraC demonstrated no
significant changes in the activity of the nuclear proteasome within 60 minutes, respectively (Figure 1).
Whereas tumor cells in distinct states of development may respond
differently to the same antitumor chemotherapy, we investigated the
enzymatic activity and regulation of the nuclear proteasome after
adriamycin treatment in certain cell variants of U937 cells. Thus,
proliferating U937 cells, nonproliferating TPA-differentiated cells
(Diff-U937), retrodifferentiated cells (Retro-U937), as well as the
aggressively tumor-developing U937 subclone TUR were treated with
sublethal concentrations of adriamycin in a time-dependent manner for
up to 60 minutes. The constitutive nuclear proteasomal activity in U937
control cells increased about 4.3-fold after 15 minutes of adriamycin
treatment and returned to control level after 60 minutes (Figure
2, left panel). In growth-arrested
Diff-U937 cells, the constitutive nuclear proteasomal activity was
significantly reduced and demonstrated little if any difference after
adriamycin treatment. However, when the proliferative capacity resumed
in Retro-U937 cells, the proteasome activity was comparable to the level observed in U937 control cells both constitutively and after adriamycin-induced oxidative stress (Figure 2, left panel). Moreover, the highly tumorigenic U937 subclone TUR demonstrated a 1.5-fold elevated constitutive proteasomal activity as compared with U937 cells,
which increased to about 5.8-fold after adriamycin treatment (Figure 2,
left panel).
Our recent studies have suggested a possible regulatory involvement of PARP during H2O2-induced activation of the nuclear proteasome,21 and similar results were obtained in adriamycin-treated human leukemia cells (Figure 2, right panel). Thus, inhibition of PARP by addition of 3-ABA significantly reduced the adriamycin-induced proteasome activity in proliferating U937, Retro-U937, and TUR cells by about 50%, respectively (Figure 2, right panel). In contrast, the low constitutive proteasome activity in growth-arrested Diff-U937 cells remained unchanged following PARP inhibition by 3-ABA (Figure 2, right panel). Taken together, these data suggested an important role of PARP in the regulation of adriamycin-induced proteasome activity that is associated with the proliferative capacity and the state of development in leukemic cells. To address this point, we investigated possible interactions between
PARP and the proteasome by coimmunoprecipitation experiments. Adriamycin treatment of U937 cells for up to 60 minutes was followed by
an anti-PARP immunoprecipitation of nuclear proteins and subsequent anti-PARP and antiproteasome Western blotting (Figure
3A). Anti-PARP immunoprecipitates
demonstrated little if any differences in the level of PARP protein
(Figure 3A). In contrast, proteasome-specific subunits were detected
exclusively in adriamycin-treated cells, and inhibition of PARP by
3-ABA strongly reduced the coprecipitation of proteasome subunits
(Figure 3A). To test if these coprecipitates contained only certain
proteasome subunits or the functional active proteasome, we also
measured the proteasomal enzymatic activity in the anti-PARP
immunoprecipitates (Figure 3B). Thus, the proteasomal enzymatic
activity demonstrated a strong correlation with the amount of
coprecipitated proteasome protein (Figure 3A-B). These data suggested
that after oxidative stress, increasing levels of functionally active
proteasome complex become associated with PARP. Moreover, inhibition of
PARP by 3-ABA significantly reduced the association with the proteasome
complex and consequently diminished proteasome activity.
To compare the extent of this PARP-proteasome interaction in the
different leukemic cell variants, U937, Diff-U937, Retro-U937, and TUR
cells were treated with adriamycin for maximal nuclear proteasome
activity (15 minutes) followed by extraction of nuclear proteins and
anti-PARP immunoprecipitation (Figure 4).
Subsequent anti-PARP Western blotting revealed little if any
differences in the level of precipitated PARP protein throughout the 4 investigated cell types (Figure 4A). In contrast, most of the
coprecipitated proteasome complex was demonstrated by TUR cells when
compared with U937 and Retro-U937 cells, whereas the proteasome was
undetectable in Diff-U937 (Figure 4A). Similar results were obtained
when the proteasomal activity was measured in the anti-PARP
immunoprecipitates of these 4 cell types in the absence and presence of
the PARP inhibitor 3-ABA (Figure 4B). Taken together, these studies
confirm the association of the functionally active proteasome complex with PARP in oxidatively stressed cells; however, the different levels
of proteasome association in the 4 different cell types suggested
altered antioxidative defense mechanisms depending on the state of
development. We therefore investigated the adriamycin toxicity in U937
cells and in the highly chemotherapy-resistant TUR cells (Figure
5). In this experiment U937 and TUR cells
were preincubated with the selective proteasome inhibitor MG-132 or with the PARP-inhibitor 3-ABA and then treated with various adriamycin concentratrions. The amount of remaining viable cells after 24 hours is
demonstrated in Figure 5A. In all applied concentrations, adriamycin
exhibited an antiproliferative effect on U937 cells and a median lethal
dose (LD50) of about 3 × 10
To obtain more detailed insights into these effects, we used U937 and
TUR cell clones stably transfected with an asPARP expression vector,
because functional knockouts of the proteasome contribute to
severe cell damage and subsequent apoptosis.15 The
successful and highly specific function of the asPARP transfectants was
investigated by anti-PARP Western blots (Figure 5B). TUR and U937
control cells express PARP proteins in contrast to the U937 and TUR
asPARP transfectants, respectively (Figure 5B). These effects occur
without impairment of proteasome protein expression as demonstrated by
similar protein levels in each lane of the antiproteasome Western blots
(Figure 5B). Whereas U937 and TUR control vector transfectants
exhibited similar effects when compared with U937 and TUR cells,
respectively (data not shown), adriamycin treatment of asPARP-TUR cells
demonstrated an LD50 of about 2 × 10 These data suggested that functionally active PARP may contribute to
protect leukemic cells from cytotoxic effects after about 24 hours of
drug treatment by a transient process of proteasome activation within
15 minutes to 30 minutes. To address this question, we investigated the
adriamycin-induced nuclear protein and DNA damage in U937 and TUR cells
within 24 hours. DNA-protein cross-links could be detected after 15 minutes of adriamycin treatment (Figure 6A,B). Whereas in U937 cells the
cross-links disappeared after 15 minutes, there was a significantly
progressive accumulation following inhibition of PARP by 3-ABA and in
asPARP-U937 cells within 24 hours, respectively (Figure 6A-B).
Moreover, the steady-state level of intranuclear oxidatively modified
proteins remained unchanged in U937 cells following a transient
increase after 15 minutes of adriamycin treatment (Figure 6C). In
contrast, oxidatively modified proteins significantly accumulated in
U937 cells with inhibited PARP and in asPARP-U937 cells within 24 hours
(Figure 6C). Previous work has demonstrated that protein cross-links
can inhibit the proteasome activity.41,46 Thus, nuclear
proteasome activity following adriamycin treatment revealed a
significantly decreasing activity in U937 cells with inhibited PARP and
in asPARP-U937 after 24 hours of adriamycin treatment (Figure 6D). In
parallel, alkaline single-cell electrophoresis revealed an increased
DNA damage after 15 minutes of adriamycin treatment in all cell types; however, U937 cells with inhibited PARP or asPARP-U937 cells
demonstrated a strong accumulation of damaged DNA between 1 hour and 24 hours (Figure 6E). Of interest, the formation and accumulation of
DNA-protein cross-links preceded the accumulation of DNA damage,
suggesting that these cross-links might interfere with DNA repair
during continuous adriamycin-induced damage. Similar results were
obtained for TUR cells and asPARP-TUR cells (data not shown).
To test the functional involvement of PARP in the regulation of
adriamycin-activated nuclear proteasome beyond the cell culture model, we isolated leukemic blasts from previously untreated
patients suffering from AML. The leukemic blasts were transiently
transfected with the control vector and the asPARP vector,
respectively, and cultured for up to 60 minutes in the presence of
adriamycin. In close similarity to the time course of the cell culture
model, the proteasome activity in human leukemic blasts increased after in vitro adriamycin treatment and was markedly reduced after PARP inhibiton by 3-ABA or after PARP depletion by asPARP transfection (Figure 7A). The successful function of
the transient asPARP transfection was investigated by Western blot
analysis. Whereas proteasome protein expression was equally distributed
throughout the different samples, anti-PARP Western blots demonstrated
significant levels of PARP proteins in the leukemic blasts and the
control vector blasts in contrast to the low levels observed in the
asPARP blasts (Figure 7B). Anti-GFP Western blots documented the
transfection controls, and antiactin demonstrated the equal loading
controls, respectively (Figure 7B).
Anti-PARP immunoprecipitation of human leukemic blast lysates after adriamycin treatment revealed similar PARP protein levels throughout the 60-minute time course (Figure 7C). In contrast, the coprecipitation of distinct proteasome complexes was only detectable between 5 minutes and 30 minutes after adriamycin treatment, with a maximum level after about 15 minutes (Figure 7C). Moreover, inhibition of PARP by 3-ABA was associated with a significantly reduced coprecipitation of proteasome (Figure 7C). Taken together, these results in leukemic blasts are in agreement with our findings in the leukemic cell culture model and thus support an involvement of PARP in the proteasome activation during an adriamycin-based chemotherapy.
Anthracyclines are part of most chemotherapeutic regimes in hematologic oncology, and resistance to these drugs causes major complications during the therapy. Anthracyclines progressively accumulate in the nuclei of hematopoietic cells and reach peak concentrations approximately 8 minutes after administration.47 Certain anthracyclines, including adriamycin, develop oxygen radicals to derail nuclear protein functions, ie, by oxidation of histones and damage of DNA. As a major component of the antioxidative defense system in the nucleus, adriamycin treatment contributed to an activation of the 20S proteasome. Previous work has demonstrated that up-regulation of several antioxidant enzyme activities like superoxide dismutase, catalase, and glutathione peroxidase is associated with adriamycin treatment.48 Moreover, enhanced proteasome activity19,20 and activation of PARP has been demonstrated in human tumor cells following chemotherapy.4-6,31 We were therefore interested if the proteasome activity is associated with PARP activation after adriamycin treatment. Indeed, inhibition of PARP by 3-ABA abolished most of the proteasome enzyme activity following adriamycin administration of proliferating leukemia cells. Interestingly, aggressive tumor-developing TUR cells revealed an enhanced constitutive and adriamycin-inducible proteasome activity when compared with the parental U937 control and Retro-U937 cells, whereas the proteasome activity in nonproliferating Diff-U937 cells was constitutively reduced and little if any change was observed after adriamycin treatment. These findings indicate that activation of an antioxidative defense system might be used particularly by proliferating tumor cells to cope with nuclear damages induced by chemotherapeutic agents because the selective and efficient degradation of oxidatively damaged nuclear proteins appears to be a requirement for maintaining genomic integrity. Thus, previous work has suggested that up-regulation of an antioxidative defense system is involved in adaptive response and resistance development against antitumor chemotherapy.49 Consequently, tumor cells can acquire a certain insensitivity or resistance against chemotherapeutic agents in the course of treatment.50,51 In this context, aggressively proliferating and tumor-developing human TUR leukemic cells exhibit such a resistance against drug-induced differentiation and apoptosis.52 Previous studies have demonstrated, however, that these resistance features developed by TUR cells are independent of a p-glycoprotein up-regulation53 and are therefore based on a novel mechanism. To get closer insights into the cellular defense mechanisms of these leukemic cells, coimmunoprecipitation experiments revealed interactions between PARP and the nuclear proteasome activation after adriamycin administration. Thus, the coprecipitated proteasome subunit levels and subsequent enzymatic activities demonstrated a strong correlation after incubation with adriamycin. Following PARP inhibition with 3-ABA in adriamycin-treated cells, however, the coprecipitated proteasome subunits and, accordingly, the proteasomal proteolytic activity was significantly reduced in the presence of unaltered PARP protein levels. This indicates an interaction of the proteasome with PARP via poly(ADP-ribose) chains, because previous work has demonstrated in vitro that poly(ADP-ribose) chains can attach to the functionally active PARP during the automodificaton reaction and thus contribute to an enhanced proteolytic activity.23 Consequently, an increased PARP automodification in proliferating leukemic cells such as U937 and TUR provides a potential to develop chemotherapeutic resistance by elevating the proteasome metabolic activity. To verify PARP as a possible primary target within chemotherapeutic defense mechanisms developed by certain tumor cells, we selected U937 and TUR cell clones stably transfected with a constitutively active asPARP vector. Adriamycin treatment revealed a 4-fold increased sensitivity in asPARP-U937 cells and a 25-fold increased sensitivity in asPARP-TUR cells as compared with the appropriate wild-type cells, respectively. Thus, we could show that the initially high adriamycin resistance of TUR cells can be significantly reduced by specific depletion of the PARP protein. In this context, the observed reduction and subsequent decline of proteasome activity in 3-ABA-treated or asPARP cells within 24 hours suggests a causal relationship to the protein cross-link formation following adriamycin treatment. Indeed, previous studies have documented that carbon-centered protein radicals and protein carbonyls can react with nucleobases and thus form DNA-protein cross-links.54,55 Moreover, anthracyclins can initiate the formation of DNA-protein cross-links and DNA interstrand cross-links.56,57 Furthermore, recent work has also demonstrated that DNA-protein cross-links are involved in the inhibition of the proteasome.41 Consequently, the declining proteasome activity in PARP-inhibited cell populations enhances further formation and accumulation of oxidatively damaged protein products and protein-DNA cross-links, which contribute to a progressive DNA damage and subsequent cell death. Activation of the nuclear proteasome system could therefore be considered as an intranuclear antioxidative defense system that prevents the accumulation of oxidatively damaged proteins beyond a critical threshold. The clinical relevance of these findings was tested in isolated monocytic leukemia cells from patients with acute myelocytic leukemia (AML subtype M5) prior to initial chemotherapeutic treatment. PARP inhibition by 3-ABA and specific PARP depletion by transient transfection of these human leukemic blasts with the asPARP vector confirmed a significant reduction of proteasome activity after adriamycin treatment, respectively. Moreover, although the proteasome subunit patterns in leukemic blasts appear different to those observed in the 4 leukemic cell line variants, the time course of maximal interaction with PARP and the sensitivity to PARP inhibition are similar in the coimmunoprecipitation experiments. Taken together, these findings suggest that the regulation of the proteasome activity in adriamycin-treated leukemic cells is associated with functionally active PARP and paralleled by a certain level of chemotherapeutic resistance. Whereas oxidatively damaged proteins induce PARP for poly-ADP-ribosylation of both the damaged proteins and PARP itself, the automodified form of PARP may contribute to activate the proteasome subunits.23 PARP could therefore be considered as a potential target for strategies to potentiate the chemotherapeutic sensitivity and thus to reduce primary or secondary resistance mechanisms.
Submitted July 19, 2000; accepted January 7, 2001.
Ö.C. and O.U. contributed equally to this work.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Ralf Hass, Biochemistry and Tumor Biology, Clinic of Obstetrics and Gynecology (OE 6410), Medical School/Oststadtkrankenhaus, Podbielskistr 380, D-30659 Hannover, Germany; e-mail: hass.ralf{at}mh-hannover.de.
1. Preisler HD, Anderson K, Rai K, et al. The frequency of long-term remission in patients with acute myelogenous leukemia treated with concentional maintenance chemotherapy: a study of 760 patients with a minimal follow-up time of 6 years. Br J Haematol. 1989;71:189-194[Medline] [Order article via Infotrieve].
2.
Champlin R, Gale RP.
Acute myelogenous leukemia: recent advances in therapy.
Blood.
1987;69:1551-1562
3.
Weinstein HJ, Mayer RJ, Rosenthal DS, Coral FS, Camitta BM, Gelber RD.
Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update.
Blood.
1983;62:315-319 4. Ruf A, de Murcia G, Schulz GE. Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling. Biochemistry. 1998;37:3893-3900[CrossRef][Medline] [Order article via Infotrieve]. 5. Watson CY, Whish WJ, Threadgill MD. Synthesis of 3-substituted benzamides and 5-substituted isoquinolin-1(2H)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP). Bioorg Med Chem. 1998;6:721-734[CrossRef][Medline] [Order article via Infotrieve]. 6. Boulikas T. Poly(ADP-ribosyl)ation, DNA strand breaks, chromatin and cancer. Toxicol Lett. 1993;67:129-150[CrossRef][Medline] [Order article via Infotrieve]. 7. Sinha BK, Mimnaugh EG. Free radicals and anticancer drug resistance; oxygen free radicals in the mechanisms of drug cytotoxicity and resistance by certain tumors. Free Radic Biol Med. 1990;8:567-581[CrossRef][Medline] [Order article via Infotrieve].
8.
Davies KJA, Doroshow JH.
Redox cycling of anthracyclines by cardiac mitochondria, I: anthracycline radical formation by NADH dehydrogenase.
J Biol Chem.
1986;261:3060-3067
9.
Doroshow JH, Davies KJA.
Redox cycling of anthracyclines by cardiac mitochondria, II: formation of superoxide anion, hydrogen peroxide, and hydroxyl radical.
J Biol Chem.
1986;261:3068-3074 10. Marcillat O, Zhang Y, Davies KJA. Oxidative and non-oxidative mechanisms in the inactivation of cardiac mitochondrial electron transport chain components by doxorubicin. Biochem J. 1989;259:181-189[Medline] [Order article via Infotrieve]. 11. Feinstein E, Canaani E, Weiner LM. Dependence of nucleic acid degradation on in situ free-radical production by adriamycin. Biochemistry. 1993;32:13156-13161[CrossRef][Medline] [Order article via Infotrieve].
12.
Enright HU, Miller WJ, Hebbel RP.
Nucleosomal histone proteins protects DNA from iron-mediated damage.
Nucleic Acid Res.
1992;20:3341-3346
13.
Jones NJ, Ellard S, Waters R, Parry EM.
Cellular and chromosomal hypersensitivity to DNA crosslinking agents and toposiomerase inhibitors in the radiosensitive Chinese hamster irs mutants: phenotypic similarities to ataxia teleangiectasia and Fanconi's anaemia cells.
Carcinogenesis.
1993;14:2487-2494
14.
Davies KJA.
Protein damage and degradation by oxygen radicals.
J Biol Chem.
1987;262:9895-9901 15. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem. 1996;65:801-847[CrossRef][Medline] [Order article via Infotrieve].
16.
Grune T, Reinheckel T, Davies KJA.
Protein degradation in cultured liver epithelial cells during oxidative stress: role of the multicatalytic proteinase complex, proteasome.
J Biol Chem.
1995;270:2344-2351
17.
Grune T, Reinheckel T, Davies KJA.
Degradation of oxidized proteins in K562 human hematopoietic cells by proteasome.
J Biol Chem.
1996;271:15504-15509 18. Ullrich O, Sitte N, Sommerburg O, Sandig V, Davies KJA, Grune T. Influence of DNA binding on the degradation of oxidized histones by the 20S proteasome. Arch Biochem Biophys. 1999;362:211-216[CrossRef][Medline] [Order article via Infotrieve].
19.
Kumatori A, Tanaka K, Inamura N, et al.
Abnormally high expression of proteasomes in human leukemic cells.
Proc Natl Acad Sci U S A.
1990;87:7071-7075
20.
Shimbara N, Orino E, Sone S, et al.
Regulation of gene expression of proteasomes (multi-protease complex) during growth and differentiation of human hematopoietic cells.
J Biol Chem.
1992;267:18100-18109
21.
Ullrich O, Reinheckel T, Sitte N, Hass R, Grune T.
Poly-ADP-ribose-polymerase activates nuclear proteasome to degrade oxidatively damaged histones.
Proc Natl Acad Sci U S A.
1999;96:6223-6228
22.
Yoon YS, Kim JW, Kang KW, Kim JS, Choi KH, Joe CO.
Poly(ADP-ribosyl)ation of histone H1 correlates with internucleosomal DNA fragmentation during apoptosis.
J Biol Chem.
1996;271:9129-9134 23. Meyer-Kuckuk P, Ullrich O, Grune T, Ziegler M, Schweiger M. Poly(ADP-ribosyl)transferase interacts with the 20S proteasome in vitro. Biochem Biophys Res Commun. 1999;259:576-581[CrossRef][Medline] [Order article via Infotrieve]. 24. De Murcia G, Schreiber V, Molinete M, et al. Structure and function of poly(ADP-ribose) polymerase. Mol Cell Biochem. 1994;138:15-24[CrossRef][Medline] [Order article via Infotrieve]. 25. Daugherty JP, Simpson TA Jr. Effect of adriamycin and hyperthermia on the sedimentation of nucleoids from L1210 cells. Int J Radiat Biol Relat Stud Phys Chem Med. 1988;53:367-380[Medline] [Order article via Infotrieve]. 26. Tanizawa A, Kubota M, Takimoto T, et al. Prevention of adriamycin-induced interphase death by 3-aminobenzamide and nicotinamide in a human promyelocytic cell line. Biochem Biophys Res Commun. 1987;144:1031-1036[CrossRef][Medline] [Order article via Infotrieve].
27.
Tentori L, Lacal PM, Benincasa E, et al.
Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly(ADP-ribose)polymerase.
J Pharmacol Exp Ther.
1998;285:884-893
28.
Chatterjee S, Cheng MF, Berger RB, Berger SJ, Berger NA.
Effect of inhibitors of poly(ADP-ribose)polymerase on the induction of GRP78 and subsequent development of resistance to etoposide.
Cancer Res.
1995;55:868-873 29. Nagao M, Nakayasu M, Aonuma S, Shima H, Sugimura T. Loss of amplified genes by poly(ADP-ribose)poylmerase inhibitors. Environ Health Perspect. 1991;93:169-174[Medline] [Order article via Infotrieve]. 30. Berger NA, Berger SJ, Gerson SL. DNA repair, ADP-ribosylation and pyridine nucleotide metabolism as targets for cancer chemotherapy. Anticancer Drug Des. 1987;2:203-209[Medline] [Order article via Infotrieve]. 31. Kato T, Suzumura Y, Fukushima M. Enhancement of bleomycin activity by 3-aminobenzamide, a poly(ADP-ribose) synthesis inhibitor, in vitro and in vivo. Anticancer Res. 1988;8:239-243[Medline] [Order article via Infotrieve]. 32. Hass R, Bartels H, Topley N, et al. TPA-induced differentiation and adhesion of U937 cells: changes in ultrastructure, cytoskeletal organization and expression of surface antigens. Eur J Cell Biol. 1989;48:282-293[Medline] [Order article via Infotrieve].
33.
Hass R, Gunji H, Datta R, et al.
Differentiation and retrodifferentiation of human myeloid leukemia cells is associated with reversible induction of cell cycle regulation genes.
Cancer Res.
1992;52:1445-1450 34. Hass R, Hirano M, Kharbanda S, Rubin E, Meinhardt G, Kufe D. Resistance to phorbol-ester-induced differentiation of a U937 myeloid leukemia cell variant with a signaling defect upstream to Raf-1 kinase. Cell Growth Differ. 1993;4:657-663[Abstract].
35.
Rovera G, O'Brian TA, Diamond L.
Induction of differentiation in human promyelocytic leukemia cells by tumor promoters.
Science.
1979;204:868-870 36. Hass R, Meinhardt G, Hadam M, Bartels H. Characterization of human TUR leukemia cells: continued cell cycle progression in the presence of phorbol ester is associated with resistance to apoptosis. Eur J Cell Biol. 1994;65:408-416[Medline] [Order article via Infotrieve]. 37. Hass R, Lopez-Guerrero J. Aggressive tumor growth of the human TUR leukemic cells is associated with high levels of c-myc expression and down-regulation of p20-max. Int J Cancer. 1997;72:1113-1116[CrossRef][Medline] [Order article via Infotrieve].
38.
Emig S, Schmalz D, Shakibaei M, Buchner K.
The nuclear pore complex protein p62 is one of several sialic acid-containing proteins of the nuclear envelope.
J Biol Chem.
1995;270:13787-13793 39. Zwilling S, Koenig H, Wirth T. High mobility group protein 2 functionally interacts with the POU domains of octamer transcription factors. EMBO J. 1995;14:1198-2008[Medline] [Order article via Infotrieve]. 40. Reznick AZ, Packer L. Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol. 1994;233:357-363[Medline] [Order article via Infotrieve]. 41. Ullrich O, Sitte N, Sommerburg O, et al. Influence of DNA binding on the degradation of oxidized histones by the 20S proteasome. Arch Biochem Biophys. 1999;363:211-216. 42. Kruszewski M, Iwanenko T, Bouzyk E, Szumiel I. Chelating of iron and copper alters properties of DNA in L5178Y cells, as revealed by the comet assay. Mutat Res. 1999;434:53-60[Medline] [Order article via Infotrieve].
43.
Lipinski P, Drapier JC, Oliveira L, Retmanska H, Sochanowicz B, Kruszewski M.
Intracellular iron status as a hallmark of mammalian cell susceptibility to oxidative stress: a study of L5178Y mouse lymphoma cell lines differentially sensitive to H(2)O(2).
Blood.
2000;95:2960-2966 44. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988;175:184-191[CrossRef][Medline] [Order article via Infotrieve].
45.
Ame JC, Rolli V, Schreiber V, et al.
PARP-2: A novel mammalian DNA-damage-dependent poly(ADP-ribose) polymerase.
J Biol Chem.
1999;274:17860-17868 46. Grune T, Reinheckel T, Davies KJ. Degradation of oxidized proteins in mammalian cells. FASEB J. 1997;11:526-534[Abstract]. 47. Gieseler F, Biersack H, Brieden T, Manderscheid J, Nuessler V. Cytotoxicity of anthracyclines: correlation with cellular uptake, intracellular distribution and DNA binding. Acta Hematol. 1994;69:S13-S17. 48. Yin X, Wu H, Chen Y, Kang YJ. Induction of antioxidants by adriamycin in mouse heart. Biochem Pharmacol. 1998;56:87-93[CrossRef][Medline] [Order article via Infotrieve]. 49. Vanella A, Campisi A, di Giacomo C, Sorrenti V, Vanella G, Acquaviva R. Enhanced resistance of adriamycin-treated MCR-5 lung fibroblasts by increased intracellular glutathione peroxidase and extracellular antioxidants. Biochem Mol Med. 1997;62:36-41[CrossRef][Medline] [Order article via Infotrieve]. 50. Minowada J. Immunology of leukaemia. In: Gunz F,Henderson E, eds. Immunology of Leukemic Cells.; 1982. 51. Borella L, Sen L. T cell surface markers on lymphoblasts from acute leukemia. J Immunol. 1973;111:1251-1260.
52.
Meinhardt G, Roth J, Totok G, Auner H, Emmerich B, Hass R.
Signaling defect in the activation of caspase-3 and PKC 53. Meinhardt G, Roth J, Hass R. Activation of protein kinase C relays distinct signaling pathways in the same cell type: differentiation and caspase-mediated apoptosis. Cell Death Differ. 2000;7:795-803[CrossRef][Medline] [Order article via Infotrieve]. 54. Ostdal H, Skibsted LH, Andersen HJ. Formation of long-lived protein radicals in the reaction between H2O2-activated metmyoglobin and other proteins. Free Radic Biol Med. 1997;23:754-761[CrossRef][Medline] [Order article via Infotrieve]. 55. von Sonntag C. The chemistry of free-radical-mediated DNA-damage. Basic Life Sci. 1991;58:287[Medline] [Order article via Infotrieve]. 56. Dong J, Naito M, Tatsuta T, Seimiya H, Johdo O, Tsuruo T. Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines. Oncol Res. 1995;7:245-252[Medline] [Order article via Infotrieve].
57.
Cutts SM, Parsons PG, Sturm RA, Philips DR.
Adriamycin-induced DNA adducts inhibit the DNA interactions of transcription factors and RNA polymerase.
J Biol Chem.
1996;271:5422-5429
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  J. Liu, H. Zheng, M. Tang, Y.-C. Ryu, and X. Wang A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2541 - H2550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bertram and R. Hass Matrix Metalloproteinase-7 and the 20S Proteasome Contribute to Cellular Senescence Sci. Signal., March 25, 2008; 1(12): pt1 - pt1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Attar, D. J. DeAngelo, J. G. Supko, F. D'Amato, D. Zahrieh, A. Sirulnik, M. Wadleigh, K. K. Ballen, S. McAfee, K. B. Miller, et al. Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia Clin. Cancer Res., March 1, 2008; 14(5): 1446 - 1454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yanagawa, T. Funasaka, S. Tsutsumi, H. Hu, H. Watanabe, and A. Raz Regulation of Phosphoglucose Isomerase/Autocrine Motility Factor Activities by the Poly(ADP-Ribose) Polymerase Family-14 Cancer Res., September 15, 2007; 67(18): 8682 - 8689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Small, S. Somasundaram, D. T. Moore, Y. Y. Shi, and R. Z. Orlowski Repression of Mitogen-Activated Protein Kinase (MAPK) Phosphatase-1 by Anthracyclines Contributes to Their Antiapoptotic Activation of p44/42-MAPK J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 861 - 869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Virag and C. Szabo The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors Pharmacol. Rev., September 1, 2002; 54(3): 375 - 429. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
), 10
), or 10
), were isolated and lysed and the degradation of
lactacystin-senstive suc-LLVY-MCA was quantified as proteasomal
activity. Data are given as mean ± SD (n = 4).
3-ABA. Nuclei from U937, Diff-U937, Retro-U937, and TUR cells
were isolated and lysed after treatment with 10
, Diff-U937; 
, TUR.
in human TUR leukemia cells is associated with resistance to apoptosis.
Exp Cell Res.
1999;247:534-542